Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686226 · ClinicalTrials.gov registry record · Phase 2
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
A Phase 2 study of Cervical Cancer and Metastatic Cancer, sponsored by Christian Hinrichs.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT05686226: Recruiting Phase 2 study of Cervical Cancer and Metastatic Cancer, sponsored by Christian Hinrichs.
NCT05686226 is a Phase 2 study of Cervical Cancer and Metastatic Cancer that is actively recruiting participants, run by Christian Hinrichs. The registered enrollment target is 20 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05686226, a Phase 2 study of Cervical Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Christian Hinrichs.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.
Primary Outcome
Objective tumor response as measured by RECIST
Conditions Studied
Interventions
- DRUG Aldesleukin
- BIOLOGICAL E7 TCR-T cells
Study Locations (3)
New Jersey
- Rutgers Cancer Institute - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 2 |
What NCT05686226 shows while recruiting
NCT05686226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower).
The record links to 10 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aldesleukin is the first listed.
NCT05686226 reports a single indexed study location in New Jersey, Maryland.
Frequently Asked Questions
What is clinical trial NCT05686226 about?
NCT05686226 is a clinical study titled "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers". This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR...
What is the current status of trial NCT05686226?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-03-07. Estimated completion is 2027-01-01.
What conditions does trial NCT05686226 study?
This clinical trial studies the following conditions: Cervical Cancer, Metastatic Cancer, Oropharynx Cancer, Anal Cancer, Vaginal Cancer.
What interventions are being tested in trial NCT05686226?
The interventions under investigation include: Aldesleukin (DRUG), E7 TCR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05686226?
This trial is sponsored by Christian Hinrichs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05686226 being conducted?
This trial has 3 study locations across Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05686226's enrollment target sits among peer trials
20 131st of 144 higher than 10 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI